Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study
- 23 September 2022
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 33 (3) , 1653-1667
Abstract
Objectives To investigate the value of R2* mapping–based radiomics nomograms in staging liver fibrosis in patients with chronic hepatitis B. Methods Between January 2020 and December 2020, 151 patients with chronic hepatitis B were randomly divided into training (n = 103) and validation (n = 48) cohorts. From January to February 2021, 58 patients were included in a test cohort. Radiomics features were selected using the interclass correlation coefficient and least absolute shrinkage and selection operator method. Three radiomics nomograms, combining the radiomics score (Radscore) derived from R2* mapping and clinical variables, were used for staging significant and advanced fibrosis, and cirrhosis. Performance of the model was evaluated using the AUC. The utility and clinical benefits were evaluated using the continuous net reclassification index (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). Results The Radscore calculated by 12 radiomics features and independent factors (laminin and platelet) of advanced fibrosis were used to construct the radiomics nomograms. In the test cohort, the AUCs of the radiomics nomograms for staging significant fibrosis, advanced fibrosis, and cirrhosis were 0.738 (95% confidence interval [CI]: 0.604–0.872), 0.879 (95% CI: 0.779–0.98), and 0.952 (95% CI: 0.878–1), respectively. NRI, IDI, and DCA confirmed that radiomics nomograms demonstrated varying degrees of clinical benefit and improvement for advanced fibrosis and cirrhosis, but not for significant fibrosis. Conclusions Radiomics nomograms combined with R2* mapping–based Radscore, laminin, and platelet have value in staging advanced fibrosis and cirrhosis but limited value for staging significant fibrosis. Key Points • Laminin and platelets were independent predictors of advanced fibrosis. • Radiomics analysis based on R2* mapping was beneficial for evaluating advanced fibrosis and cirrhosis. • It was difficult to distinguish significant fibrosis using a radiomics nomogram, which is possibly due to the complex pathological microenvironment of chronic liver diseases.Keywords
This publication has 48 references indexed in Scilit:
- A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival dataStatistics in Medicine, 2012
- Radiomics: Extracting more information from medical images using advanced feature analysisEuropean Journal of Cancer, 2012
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Multiecho reconstruction for simultaneous water‐fat decomposition and T2* estimationJournal of Magnetic Resonance Imaging, 2007
- Decision Curve Analysis: A Novel Method for Evaluating Prediction ModelsMedical Decision Making, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Liver iron deposits in hepatitis B patients: Association with severity of liver disease but not with hemochromatosis gene mutationsJournal of Gastroenterology and Hepatology, 2004
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic valueJournal of Hepatology, 1996
- Classification of chronic viral hepatitis: a need for reassessmentJournal of Hepatology, 1991